Stay updated on SBRT ± Nivolumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SBRT ± Nivolumab in NSCLC Clinical Trial page.

Latest updates to the SBRT ± Nivolumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedA banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434. It appears above the page’s 403 error message.SummaryDifference1%

- Check8 days agoChange DetectedThe study page continues to display a 403 Forbidden error. Its footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check15 days agoChange DetectedThe site's displayed revision identifier changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedRevision: v3.7.0 was added to the page, and several institutional names and related terms were removed from the study details. This change alters the listed locations and collaborators shown for the trial, affecting how the study is presented to readers.SummaryDifference20%

- Check56 days agoChange DetectedRevision: v3.6.6 is now shown on the page, replacing the previous v3.6.5. The update appears to be a technical version change rather than a substantive modification to the study information.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page’s revision tag was updated from v3.6.4 to v3.6.5, replacing the previous version identifier. This signals an internal update to the site’s template or CMS rather than changes to visible content.SummaryDifference0.1%

Stay in the know with updates to SBRT ± Nivolumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT ± Nivolumab in NSCLC Clinical Trial page.